These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24604591)

  • 41. Preliminary biological evaluation of ¹²⁵I-labeled anti-carbonic anhydrase IX monoclonal antibody in the mice bearing HT-29 tumors.
    Li J; Shi L; Wang C; Zhang X; Jia L; Li X; Zhou W; Qi Y; Zhang L
    Nucl Med Commun; 2011 Dec; 32(12):1190-3. PubMed ID: 21968435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
    Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM
    Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.
    Viola-Villegas NT; Sevak KK; Carlin SD; Doran MG; Evans HW; Bartlett DW; Wu AM; Lewis JS
    Mol Pharm; 2014 Nov; 11(11):3965-73. PubMed ID: 24779727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.
    Divgi CR; Pandit-Taskar N; Jungbluth AA; Reuter VE; Gönen M; Ruan S; Pierre C; Nagel A; Pryma DA; Humm J; Larson SM; Old LJ; Russo P
    Lancet Oncol; 2007 Apr; 8(4):304-10. PubMed ID: 17395103
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 49. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
    Lau J; Zhang Z; Jenni S; Kuo HT; Liu Z; Vullo D; Supuran CT; Lin KS; Bénard F
    Mol Pharm; 2016 Mar; 13(3):1137-46. PubMed ID: 26866675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
    Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
    Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
    Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
    PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).
    Nakaigawa N; Hasumi H; Utsunomiya D; Yoshida K; Ishiwata Y; Oka T; Hayward C; Makiyama K
    Jpn J Clin Oncol; 2024 Aug; 54(8):873-879. PubMed ID: 38864246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
    Krall N; Pretto F; Mattarella M; Müller C; Neri D
    J Nucl Med; 2016 Jun; 57(6):943-9. PubMed ID: 26912427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimization of a novel peptide ligand targeting human carbonic anhydrase IX.
    Rana S; Nissen F; Marr A; Markert A; Altmann A; Mier W; Debus J; Haberkorn U; Askoxylakis V
    PLoS One; 2012; 7(5):e38279. PubMed ID: 22693612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
    Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED
    J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
    Turkbey B; Lindenberg ML; Adler S; Kurdziel KA; McKinney YL; Weaver J; Vocke CD; Anver M; Bratslavsky G; Eclarinal P; Kwarteng G; Lin FI; Yaqub-Ogun N; Merino MJ; Linehan WM; Choyke PL; Metwalli AR
    Abdom Radiol (NY); 2016 Jan; 41(1):109-18. PubMed ID: 26830617
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.
    Zou P; Povoski SP; Hall NC; Carlton MM; Hinkle GH; Xu RX; Mojzisik CM; Johnson MA; Knopp MV; Martin EW; Sun D
    World J Surg Oncol; 2010 Aug; 8():65. PubMed ID: 20691066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology.
    Askoxylakis V; Garcia-Boy R; Rana S; Krämer S; Hebling U; Mier W; Altmann A; Markert A; Debus J; Haberkorn U
    PLoS One; 2010 Dec; 5(12):e15962. PubMed ID: 21209841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.